Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Enveric Biosciences Inc. - news published 259 - readings 4.421

BACK

Enveric Biosciences Inc.

Proxy Statement - Form DEF 14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted ...

16.04.2024

Enveric Biosciences Inc.

Shareholder Meeting - Form 8-K

Item 5.08 Shareholder Director Nominations. On March 27 2024, Enveric Biosciences, Inc. (the "Company") scheduled the Company's 2024 Annual Meeting of Stockholders (the "Annual Meeting") for May 28, 2024, which date is more than 30 days from the first anniversary of the date of the Company's 2023 Annual Meeting of Stockholders that was held on November 2, 2 ...

28.03.2024

Enveric Biosciences Inc.

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 - Form 8-K

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 Product Development Highlights: ● Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. ● Star ...

26.03.2024

Enveric Biosciences Inc.

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Press Releases Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 By wpengine March 26, 2024 No Comments Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuropl ...

26.03.2024

Enveric Biosciences Inc.

Annual Report for Fiscal Year Ending December 31, 2023 (Form 10-K)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31 , 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from ___ to ___ Commission File Number ...

26.03.2024

Enveric Biosciences Inc.

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Press Releases Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease By wpengine March 19, 2024 No Comments Second biotechnology company to potentially out-license novel compounds from Enveric's portfolio of assets with possible significant milesto ...

19.03.2024

Enveric Biosciences Inc.

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease - Form 8-K

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease Second biotechnology company to potentially out-license novel compounds from Enveric's portfolio of assets with possible significant milestone payments and royalties CAMBRIDGE, Mass., March 19, ...

19.03.2024

Enveric Biosciences Inc.

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

Press Releases Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets By wpengine March 12, 2024 No Comments Patents extend compositional protection to proprietary compounds CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the de ...

12.03.2024

Enveric Biosciences Inc.

Supplemental Prospectus - Form 424B5

Filed Pursuant to Rule 424(b)(5) Registration No. 333-257690 PROSPECTUS SUPPLEMENT (To Prospectus dated July 9, 2021) 228,690 Shares of Common Stock We are offering 228,690 shares of our common stock, par value $0.01 per share, at a deemed offering price of $1.41 per share directly to certain investors in a registered direct offering pursuant to this prospectus supplement, the ...

11.03.2024

Enveric Biosciences Inc.

Material Agreement - Form 8-K

Item 1.01 Entry Into a Material Definitive Agreement. On March 8, 2024, Enveric Biosciences, Inc., a Delaware corporation (the "Company") entered into a series of common stock purchase agreements (the "Purchase Agreement") for the issuance in a registered direct offering of 228,690 shares of the Company's common stock, par value $0.01 per share (the "S ...

11.03.2024

Enveric Biosciences Inc.

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds - Form 8-K

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds Potentially significant milestone payments and execution fees if all development and sales criteria are met for all three agreements. CAMBRIDGE, Mass., February 29, 2024 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a bi ...

29.02.2024

Enveric Biosciences Inc.

Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission FORM 4 Check this box if no longer subject to Section 16, Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investmen ...

26.02.2024

Enveric Biosciences Inc.

Statement of Changes in Beneficial Ownership - Form 4

26.02.2024

Enveric Biosciences Inc.

Statement of Changes in Beneficial Ownership - Form 4

26.02.2024

Enveric Biosciences Inc.

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Press Releases Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property By wpengine February 23, 2024 No Comments Enveric continues focused investment advancing novel neuroplastogenic molecules for the treatment of mental health disorders CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), ...

23.02.2024

Enveric Biosciences Inc. - news published 259 - readings 4.421

Enveric Biosciences Inc.

Proxy Statement - Form DEF 14A

Enveric Biosciences Inc.

Shareholder Meeting - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Enveric Biosciences Inc.

Annual Report for Fiscal Year Ending December 31, 2023 (Form 10-K)

Enveric Biosciences Inc.

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Enveric Biosciences Inc.

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

Enveric Biosciences Inc.

Supplemental Prospectus - Form 424B5

Enveric Biosciences Inc.

Material Agreement - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds - Form 8-K

Enveric Biosciences Inc.

Statement of Changes in Beneficial Ownership - Form 4

Enveric Biosciences Inc.

Statement of Changes in Beneficial Ownership - Form 4

Enveric Biosciences Inc.

Statement of Changes in Beneficial Ownership - Form 4

Enveric Biosciences Inc.

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member